Company Overview of Accera, Inc.
Accera, Inc., a biotechnology company, engages in the research, development, and commercialization of therapies for treating central nervous systems disorders, primarily neurodegenerative diseases. The company’s product pipeline includes therapeutic treatments for Parkinson's and Alzheimer's diseases, and other age-related memory loss disorders. Its products include Axona, a prescription-only medical food product for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease; and AC-1204 that targets the metabolic deficiencies and imbalances associated with Alzheimer’s disease by providing ketone bodies as an alternative energy source for ...
380 Interlocken Crescent
Interlocken Advanced Technology Park
Broomfield, CO 80021
Founded in 2001
Key Executives for Accera, Inc.
Chief Executive Officer, President and Director
Vice President of Finance, Secretary and Controller
Vice President of Research & Development
Vice President of Commercial Development
Compensation as of Fiscal Year 2014.
Accera, Inc. Key Developments
Accera, Inc. and University of Miami Announce Collaboration to Study Axona for Cognitive Impairment in Patients with Multiple Sclerosis
Apr 9 13
Accera, Inc. announced a study in collaboration with the University of Miami Miller School of Medicine. The study will examine the effects of Accera's medical food, Axona, on cognitive impairment in patients with multiple sclerosis. Axona is a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease. Drs. Melissa Ortega and Heather Katzen, two researchers at the Miller School, will serve as the primary investigators of the study. The project will be funded by Fast Forward, LLC, a nonprofit organization established by the National Multiple Sclerosis Society. More than 2.1 million people are affected by MS worldwide, and cognitive problems commonly occur in individuals with MS. Symptoms vary in severity and may have a negative impact on relationships, work and quality of life. There are few treatment options available and there is a pressing need for new interventions for cognitive impairment in MS. The UM Miller School of Medicine and Accera, with support from Fast Forward, LLC, will be testing Axona as a unique strategy for improving cognitive function in individuals with MS to address this disabling symptom.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries